

Disclaimer



This application is intended to demonstrate cost/benefit relationships based on the use of medical devices from W. L. Gore & Associates, Inc., (Gore). The data, economic assumptions and calculations used in this application model are based on currently available information. Comparative data regarding competitor devices are based on sources believed to be reliable but have not been independently verified by Gore. The user's individual results may vary depending on the specific details of the practice or hospital, and underlying data may change over time. The user remains responsible for interpreting the results and making appropriate decisions regarding the use of medical technologies. Gore does not directly or indirectly practice medicine, and decisions regarding medical treatment for patients may only be made by licensed health care providers (HCP).

All the information and results from this application are provided "as is" without guarantee or warranty, either expressed or implied. Gore is not liable for any claims or actions attributable to the use of this application model, nor for any errors or omissions involved in the use of the application or the results. Gore may update or withdraw this application at any time with no notice.

Agree

Model Specifications




See model structure

Intervention and comparators	GORE [®] SYNECOR Intraoperative Biomaterial Mesh compared to BD [®] VENTRALIGHT [®] ST Mesh
Population	Patients undergoing intraperitoneal hernia repair surgery in the U.S. Patients with wounds not considered "clean" (CDC Wound Class I) are not modeled in base case analysis
Model type	Cost-consequence and budget impact analysis Cohort level decision tree model
Perspectives and time horizon	Payers: hospitals Time horizon: 90 days
Data source(s)	Targeted rapid literature review, publicly available data (i.e., fee schedules, cost weights, etc.)
Model outcomes	Hospital: <ul style="list-style-type: none"> - Average total expected costs for hospitals through 90 days per patient treated - Incremental 90-days cost savings for hospitals per patient treated - Incremental 90-days budget impact to hospitals



Model Structure for the Management of Patients Undergoing Intraperitoneal Hernia Repair with Mesh Implant



SETTINGS

Annual intraperitoneal hernia repair procedures

600 procedures

Intervention

GORE® SYNECOR Intraperitoneal Biomaterial

Comparator

BD® VENTRALIGHT® ST Mesh

GORE® SYNECOR Intraperitoneal Biomaterial Product Mix¹

100%

CLINICAL INPUTS

	90-day Readmissions
GORE® SYNECOR Intraperitoneal Biomaterial ²⁻⁴	1.37%
BD® VENTRALIGHT® ST Mesh ⁵	11.89%

SUMMARY OF COST INPUTS

Payer Mix^{8,9}

Medicare

51%

[See model method](#)


Use of GORE® SYNECOR Intraperitoneal Biomaterial expected to result in an **estimated total cost saving of \$494** vs. competitors over 90 days

 **6%**
Cost decrease

 **\$296,562**
Total annual hospital cost decrease

-\$18
Average net operating margin per patient treated

Total Annual Hospital Costs



 Summary tables

 Sensitivity analysis



SUMMARY OF COST INPUTS

Payer Mix^{8, 9}

Medicare	51%
Private	49%

Procedure Mix^{9, 10}

Outpatient	79%
Inpatient	21%

Overall

Cost to hospital ¹¹	\$5,434
Reimbursement ¹²	\$12,250
Medicare	\$6,852
Private	\$17,834

90-day Readmission

Cost to hospital	\$15,861
Reimbursement	\$20,134
Medicare	\$11,857
Private	\$28,695
% of 90-day readmissions reimbursed	25%

[See model method](#)

Use of GORE[®] SYNECOR Intraperitoneal Biomaterial expected to result in an **estimated total cost saving of \$510** vs. competitors over 90 days



6%
Cost decrease




\$306,289
Total annual hospital
cost decrease

-\$19

Average net operating
margin per patient treated

Total Annual Hospital Costs ▼



[Summary tables](#)

[Sensitivity analysis](#)



SUMMARY OF COST INPUTS

Payer Mix^{8, 9}

Medicare	51%
Private	49%

Procedure Mix^{9, 10}

Outpatient	79%
Inpatient	21%

Overall

Cost to hospital ¹¹	\$5,434
Reimbursement ¹²	\$12,250
Medicare	\$6,852
Private	\$17,834

90-day Readmission

Cost to hospital	\$15,861
Reimbursement	\$20,134
Medicare	\$11,857
Private	\$28,695
% of 90-day readmissions reimbursed	25%

[See model method](#)

Use of GORE[®] SYNECOR Intraoperative Biomaterial expected to result in an **estimated total cost saving of \$510** vs. competitors over 90 days



6%

Cost decrease




\$306,289

Total annual hospital cost decrease

-\$19

Average net operating margin per patient treated

Avg. 90-day Cost per Patient Treated ▼



☰ Summary tables

☰ Sensitivity analysis



SUMMARY OF COST INPUTS

Payer Mix^{8, 9}

Medicare	51%
Private	49%

Procedure Mix^{9, 10}

Outpatient	79%
Inpatient	21%

Overall

Cost to hospital ¹¹	\$5,434
Reimbursement ¹²	\$12,250
Medicare	\$6,852
Private	\$17,834

90-day Readmission

Cost to hospital	\$15,861
Reimbursement	\$20,134
Medicare	\$11,857
Private	\$28,695
% of 90-day readmissions reimbursed	25%

[See model method](#)

Use of GORE[®] SYNECOR Intraoperative Biomaterial expected to result in an **estimated total cost saving of \$510** vs. competitors over 90 days



6%
Cost decrease




\$306,289
Total annual hospital
cost decrease

-\$19

Average net operating
margin per patient treated

Net Contribution Margin per Patient Treated ▼



Summary tables

Sensitivity analysis



SUMMARY OF COST INPUTS

Payer Mix^{8, 9}

Medicare	51%
Private	49%

Procedure Mix^{9, 10}

Outpatient	79%
Inpatient	21%

Overall

Cost to hospital ¹¹	\$5,434
Reimbursement ¹²	\$12,250
Medicare	\$6,852
Private	\$17,834

90-day Readmission

Cost to hospital	\$15,861
Reimbursement	\$20,134
Medicare	\$11,857
Private	\$28,695
% of 90-day readmissions reimbursed	25%

[See model method](#)

Use of GORE[®] SYNECOR Intraperitoneal Biomaterial expected to result in an **estimated total cost saving of \$510** vs. competitors over 90 days



6%
Cost decrease



\$306,289
Total annual hospital
cost decrease


-\$19

Average net operating
margin per patient treated

Clinical Outcomes ▼

per cohort

per patient



Summary tables

Sensitivity analysis



SUMMARY OF COST INPUTS

Payer Mix^{8, 9}

Medicare	51%
Private	49%

Procedure Mix^{9, 10}

Outpatient	79%
Inpatient	21%

Overall

Cost to hospital ¹¹	\$5,434
Reimbursement ¹²	\$12,250
Medicare	\$6,852
Private	\$17,834

90-day Readmission

Cost to hospital	\$15,861
Reimbursement	\$20,134
Medicare	\$11,857
Private	\$28,695
% of 90-day readmissions reimbursed	25%

[See model method](#)

Use of GORE[®] SYNECOR Intraperitoneal Biomaterial expected to result in an **estimated total cost saving of \$510** vs. competitors over 90 days



6%
Cost decrease



\$306,289
Total annual hospital
cost decrease


-\$19

Average net operating
margin per patient treated

Clinical Outcomes ▼

per cohort

per patient



[Summary tables](#)

[Sensitivity analysis](#)




Sensitivity analysis



■ Lower limit (-20%) ■ Upper limit (+20%)

Select outcome of interest: Average 90-day cost per patient treated





Cost Category**GORE® SYNECOR Intraperitoneal Biomaterial****BD® VENTRALIGHT® ST Mesh**

Avg. 90-day Cost per Patient Treated

\$7,735

\$8,246

Avg. Reimbursement per Patient Treated

\$12,319

\$12,848

Avg. Net Operating Margin per Patient Treated

\$4,584

\$4,603

vs. GORE® SYNECOR Intraperitoneal Biomaterial**\$19**



	Avg 90-day Cost per Patient Treated	Total Annual Costs to Hospital	Net Operating Margin per Patient Treated	Total Annual Net Operating Margin for Hospital
Scenario 1: No SYNECOR Intraperitoneal Device, equal mix of competitors.	\$8,245.82	\$4,947,493.73	\$4,602.62	\$2,761,573.46
Scenario 2: SYNECOR Intraperitoneal Device used in 100%	\$7,735.34	\$4,641,204.82	\$4,583.68	\$2,750,205.53
Difference	-\$510.48	-\$306,288.90	-\$18.95	-\$11,367.92

Main Menu



1. Scenario management

Scenarios:
Base scenario (complete version) 

Save

Revert

Save as

2. Additional actions



Download PDF Report

3. Closing presentation

By clicking this button you will exit the presentation and session will be marked as "Closed"

End Session

1. Assumes no uptake of GORE® SYNECOR Intraperitoneal Biomaterial in no intervention arm of economic model
2. GORE® SYNECOR Intraperitoneal Biomaterial: Weighted average of Spurzem 2024 and Linn 2022
3. Spurzem GJ, Broderick RC, Li JZ, Sandler BJ, Horgan S, Jacobsen GR. Maximizing mesh mileage: evaluating the long-term performance of a novel hybrid mesh for ventral hernia repair. *Hernia*. 2024 Aug. doi:10.1007/s10029-024-02995-0
4. Linn JG, Mallico EJ, Doerhoff CR, Grantham DW, Washington RG Jr. Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias. *Surg Endosc*. 2023 May. doi:10.1007/s00464-022-09803-9
5. Baker JJ, Öberg S, Rosenberg J. Reoperation for recurrence is affected by type of mesh in laparoscopic ventral hernia repair: a nationwide cohort study. *Ann Surg*. 2023 Feb 1. doi:10.1097/SLA.0000000000005206
6. Parker MJ, Kim RC, Barrio M, et al. A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patients. *Surg Endosc*. 2021 Sep. doi:10.1007/s00464-020-08009-1
7. Buell JF, Flaris AN, Raju S, Hauch A, Darden M, Parker GG. Long-term outcomes in complex abdominal wall reconstruction repaired with absorbable biologic polymer scaffold (poly-4-hydroxybutyrate). *Ann Surg Open*. 2021 Mar. doi:10.1097/AS9.0000000000000032
8. Data on File: PINC (Premier, Inc.) AI™ Healthcare Database (2019-2023)
9. Premier Inc. PINC AI™ Healthcare Database: 2019-2023. Charlotte, NC: 2023. (<https://offers.pinc-ai.com/PINC-AI-Healthcare-Database-White-Paper-LP.html>).
10. Premier Inc. PINC AI™ Healthcare Database: 2019-2023. Charlotte, NC: 2023. (<https://offers.pinc-ai.com/PINC-AI-Healthcare-Database-White-Paper-LP.html>).
11. Weighted average of inpatient and outpatient costs
12. Weighted average of inpatient and outpatient reimbursement across payers
13. Weighted average of Medicare and Private reimbursement
14. CMS IPPS 2024 Final Rule (DRG 353-355)
CMS PFS 2024 - Facility NPA (CPT 49613-49618)
15. Whaley CM, Kerber R, Wang D, Kofner A, Briscoombe B. Prices Paid to Hospitals by Private Health Plans: Findings from Round 5 of an Employer-Led Transparency Initiative. Santa Monica, CA: 2024. (https://www.rand.org/pubs/research_reports/RRA1144-2.html)
16. Schlosser KA, Renshaw SM, Tamer RM, Strassels SA, Poulouse BK. Ventral hernia repair: an increasing burden affecting abdominal core health. *Hernia*. 2023 Apr. doi:10.1007/s10029-022-02707-6



Please select report type



Basic (1-pager)

Detailed (2 pages with model inputs)



Generate report

How can GORE[®] SYNECOR Biomaterial help reduce treatment costs?



The following results are calculated by the budget impact model, based on health economic analysis and information provided by clinical research.

In a hospital facility performing an estimated **402** annual intraperitoneal hernia repair procedures, the use of GORE[®] SYNECOR Intraperitoneal Biomaterial results in an **estimated total cost saving of \$510** vs. competitors over 90 days


6% 
Cost decrease

\$19 
Average 90-day cost saving per patient treated

-\$11,368 
Avg. net operating margin saving per patient treated

Let us help you calculate potential savings for your facility

Avg. 90-day Cost per Patient Treated



Net Contribution Margin per Patient Treated



Report date: Feb 24, 2026

Legal address and contacts

Corporate Address
W. L. Gore & Associates
555 Paper Mill Road
Newark, DE 19711

Disclaimer

While it is designed using the latest clinical data and best practices, the interpretation and use of the tool and its results are solely the responsibility of the user. Please note, the results are for informational purposes only, and claims or rights are associated with the outcomes. All intellectual property and other rights regarding this pharmaco-economic tool (including graphical material texts, logos) belong to Gore. The content of the tool may not be published, distributed nor copied without the prior written authorization of Gore.



COST INPUTS

Payer Mix^{8, 9}

Medicare	51%
Private	49%

Procedure Mix^{9, 10}

Outpatient	79%
Inpatient	21%

Index Hernia Repair Procedure

Inpatient

Cost to hospital (minus device) ⁹	\$12,892
Reimbursement ¹³	\$22,899
Medicare ¹⁴	\$13,586
Private ¹⁵	\$32,532

Outpatient

Cost to hospital (minus device) ⁹	\$3,451
Reimbursement ¹³	\$9,420
Medicare ¹⁴	\$5,062
Private ¹⁵	\$13,927

Overall

% Outpatient ¹⁶	
Cost to hospital ¹¹	\$5,434
Reimbursement ¹²	\$12,250
Medicare	\$6,852
Private	\$17,834

90-day Readmission

Cost to hospital ⁹	\$15,861
Reimbursement	\$20,134

Consult Instructions for Use
eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available.

INDICATIONS FOR USE IN THE U.S.: The GORE® SYNECOR Intraperitoneal Biomaterial device is intended for use in the repair of hernias and abdominal wall or thoracic wall soft tissue deficiencies that may require the addition of a nonabsorbable reinforcing or bridging material. **CONTRAINDICATIONS:** The GORE® SYNECOR Intraperitoneal Biomaterial is contraindicated for use in reconstruction of cardiovascular defects.

Products listed may not be available in all markets.

© 2026 W. L. Gore & Associates, Inc. All rights reserved. All trademarks referenced are trademarks of either a member of the Gore group of affiliated companies or their respective owners. "Together, improving life" mark and design are trademarks of a Gore company. 25SS1051-EN01 25SS1058-EN01 FEBRUARY 2026

W. L. Gore and Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

